Radiopharm Theranostics Limited (ASX:RAD)
0.0100
0.00 (0.00%)
Aug 21, 2026, 4:10 PM AEST
Radiopharm Theranostics Revenue
Radiopharm Theranostics had revenue of 6.20M AUD in the half year ending December 31, 2025, with 52.60% growth. This brings the company's revenue in the last twelve months to 16.28M, up 4,823.49% year-over-year. In the fiscal year ending June 30, 2025, Radiopharm Theranostics had annual revenue of 12.51M with 538.86% growth.
Revenue (ttm)
16.28M
Revenue Growth
+4,823.49%
P/S Ratio
2.66
Revenue / Employee
1.16M
Employees
14
Market Cap
43.38M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 12.51M | 10.55M | 538.86% |
| Jun 30, 2024 | 1.96M | -4.25M | -68.46% |
| Jun 30, 2023 | 6.21M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Botanix Pharmaceuticals | 21.92M |
| Neurizon Therapeutics | 5.98M |
| Amplia Therapeutics | 4.79M |
| Arovella Therapeutics | 4.30M |
| Imugene | 3.94M |
| Noxopharm | 3.40M |
| Proteomics International Laboratories | 3.21M |
| Entropy Neurodynamics | 1.58M |
Radiopharm Theranostics News
- 1 day ago - Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial - GlobeNewsWire
- 4 days ago - Radiopharm Theranostics To Meet FDA On Phase 3 Design For RAD101; Phase 2b Shows 93% MRI Concordance - Nasdaq
- 4 days ago - Radiopharm schedules End-of-Phase 2 meeting with FDA for RAD101 - TheFly
- 4 weeks ago - Radiopharm Theranostics (RADX) Secures $4.1M in Direct Offering - GuruFocus
- 4 weeks ago - Radiopharm announces $4.1M registered direct offering - TheFly
- 4 weeks ago - Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan - GlobeNewsWire
- 4 weeks ago - Radiopharm Theranostics Reports Positive Trial Updates For RAD101 And RAD204 - Nasdaq
- 4 weeks ago - Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy - GlobeNewsWire